The car valve is one of the most common and disabling medical conditions affecting children and adults in the UK.
There are no treatments for this condition.
What’s more, the condition has been overlooked by the NHS and the medical profession for so long that many believe it is completely untreatable.
A team of scientists led by Dr Stephen Hatton from the University of Nottingham have developed a simple and affordable valve stem replacement.
It’s the first time this type of valve stem has been used in a clinical trial to test the safety and efficacy of this treatment.
The researchers say their new device could provide the NHS with a quick, affordable and safe way to treat car valve disorders.
The study, published in the journal Lancet, involved more than 1,000 children and adolescents with car valve and related conditions, with a median age of 16 years old.
They were given a series of 10 injections of a gel called GEL, which is made up of two proteins, one of which binds to a protein called CPT3 that is located on the surface of a damaged tissue.GEL works by attaching to CPT1, a protein that is normally present in the stem cells.
The researchers found that GEL helped to repair the damaged stem cells by releasing a signal that stimulates the repair of the damaged cells.
“This is an important discovery because it opens up new opportunities for treatment, for instance in children with car and respiratory conditions,” Dr Hatton said.
The device was made up out of a polymer that was already known to act as a self-cleaning barrier for the cells in the affected tissues.
The gel also contained a protein known as pvc that was designed to help to stabilize the stem and to reduce swelling in the damaged tissues.
Gel has the advantage of not having to be removed, Dr Hinton said.
“The gel is able to be placed into the patient’s mouth and the patient is able for about a minute to use the gel and to take it out.”
Dr Hatton says the gel has a very low concentration of CPT protein, which means it does not leave a residue on the affected tissue.””
The gel does not have to be changed every day.”
Dr Hatton says the gel has a very low concentration of CPT protein, which means it does not leave a residue on the affected tissue.
“What we’re trying to do is create a gel that can be injected in the patient and not have any residual protein that can accumulate on the skin,” he explained.
“We are also trying to get it into the bloodstream, so that it is released into the blood stream without causing any symptoms, as this is one way to get the gel into the brain and into the spinal cord.”
There are other things that are also being done to make the gel, such as using pvc protein as an adhesive, so it will stick better and stick longer.
“If you put a small amount of it into your mouth, you can put it into a sponge and put it on the back of a toothbrush and you’ll be able to brush it into that area,” he added.
The team are also using a combination of genetic modification and other techniques to ensure the gel is safe and effective.
“These things work in tandem, so if we do a genetic modification we can also introduce a new peptide or protein into the gel that is able, for example, to bind to the protein CPT5,” Dr Tew said.
It was hoped that this research would lead to a better understanding of the disease and the use of new therapies, but this research could also lead to the development of new treatments for other types of valve disorders and other types that could be treated by GEL.
“In our future work, we want to look at the safety profile of this gel and whether it is safe to use as an alternative to surgery,” Dr Gough said.